AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: FYCOMPA (Catalyst Pharmaceuticals) (fycompa.com)
FYCOMPA is a textbook example of regulatory-driven substance masked by a high-gloss marketing metaphor. The score remains low because pharmaceutical compliance mandates a floor of substance that most industries lack, though the stale patient data and ‘road trip’ fluff are clear BS signals. It is a professionally built site where the bullshit is primarily found in the forced optimism of its navigational metaphors.
Update all patient usage statistics (400,000 worldwide) to reflect data from the last 12 months to eliminate the ‘stale data’ penalty. Replace the navigational ‘road trip’ metaphors in H2 headings with substantive descriptors like ‘Seizure Management Protocols’ or ‘Caregiver Resource Center.’ Add a ‘Clinical Leadership’ section to the About page with links to the peer-reviewed studies supporting the AMPA receptor findings. Explicitly link the review_count metadata to a verified third-party patient experience platform.
Information density is split between high-substance regulatory text and high-fluff marketing metaphors. While the ISI blocks provide granular technical detail, the headings across the Tools and Support page rely heavily on a ‘road trip’ metaphor (Welcome to your road trip, Make time for rest stops, Missed your exit?) that lacks medical noun-density. The body substance ratio is salvaged by the inclusion of specific technical protocols like the AMPA receptor target and age-specific indications (4 years+ and 12 years+).
AI only sees the HTML that arrives on first response — everything else is invisible. Expose your real text only footprint and find out which parts of your site never reach an AI crawler at all.
There is minimal semantic drift between the homepage signal and the sub-page content. The homepage H1 ‘FYCOMPA is still available’ serves as a defensive market signal against generics, which is successfully supported by the Patient Stories and Tools pages that emphasize brand-specific support ecosystems. Cross-page messaging remains consistent, focusing on the transition from breakthrough seizures to controlled outcomes.
Move beyond vague agency reporting and visualize your surgical implementation plan. Order an Executive SEO Strategy and stop relying on superficial keyword tracking.
The site exhibits Trust Theatre through the metadata reporting review counts (e.g., review_count 7 on Tools & Support) while the body text provides zero verified review links or third-party proof paths. Furthermore, the claim of 400,000 patients worldwide is pinned to a ‘March 2021’ date; as of the May 2026 temporal anchor, this data is 62 months old (stale) and has not been updated to reflect current usage, creating a reliability gap.
Proof density is moderate; the site successfully provides a clear Prescribing Information PDF link and detailed dosage instructions for missed exits. However, the ratio of marketing fluff (road trip imagery) to verifiable clinical evidence is skewed by the age of the patient data (2021). The presence of structured schema for the drug perampanel increases the technical credibility significantly compared to non-pharma health sites.
To evaluate URL identity stability and multilingual coherence, review the Yoast Identity Stability audit. View the Yoast Identity Stability Audit for a practical example of canonical alignment and language layer integrity.
The site uses a ‘road trip’ theme to differentiate its patient resources, which is a unique positioning effort in an otherwise boilerplate industry. However, it still falls into generic pharma clichés such as ‘committed to supporting you every step of the way’ and ‘epilepsy does not define me.’ The site structure follows the standard template_fingerprints for patient-facing drug portals (Patient Stories, Tools & Support, Medication Guide).
Authority is primarily corporate (Catalyst Pharmaceuticals) rather than individual. While the schema_json includes detailed MedicalCondition and Drug entities, there is a total absence of named Medical Advisory Boards or Key Opinion Leaders (KOLs) within the text. The reliance on patient stories like Leslie and Nick provides emotional authority but leaves a gap in current clinical leadership representation.
The site makes performance claims such as ‘some patients taking FYCOMPA experienced fewer seizures,’ but the substance is relegated to footnotes stating ‘Individual results may vary.’ There is a disconnect between the optimistic ‘life full of adventure’ marketing tone and the heavy, mandatory safety warnings that occupy roughly 50% of the page real estate. No specific clinical trial data tables or peer-reviewed citations are visible in the crawled text to back the 1 in 500 suicidal thoughts metric.
Medical Devices, Pharma & Biotech BS: FYCOMPA (Catalyst Pharmaceuticals) (fycompa.com)
The site perfectly aligns with the Pharma & Biotech industry category. It provides high-substance medical indications, mechanism of action (AMPA receptor targeting), and extensive Important Safety Information (ISI) required for prescription drugs.
AI retrieval begins with one question: "What is this page?" Read the Structured Data Technical Guide to learn how correct entity typing and persistent identifiers prevent your site from collapsing into noise.
“The score of 36 is primarily driven by Information Density (metaphor fluff) and Trust Theatre (stale data and unverified review counts). The score is kept low by the excellent technical implementation of schema_json and the mandatory substance of the ISI sections. Semantic coherence is high, indicating a well-aligned but highly-marketed brand presence.”